| Literature DB >> 19104728 |
Derick van Vuuren1, Amanda Lochner.
Abstract
The increase in the incidence of ischaemic heart disease and acute myocardial infarction (AMI) in both high- and low-income countries necessitates the development of myocardial salvaging/protection interventions, to be applied alongside standard reperfusion therapies. Although the phenomenon of ischaemic preconditioning (IPC) is associated with the desired protective capacity, the necessity of its application before sustained ischaemia limits its clinical potential. The recently described phenomenon of postconditioning (postC), or short cycles of reperfusion/ischaemia applied at the onset of reperfusion, falls within the clinically relevant time period of reperfusion, but can it elicit reliable and potent cardioprotection? The answer to this problem is intimately related to the question whether postC can be translated from a laboratory technique to a clinical therapy. In this brief overview of postconditioning, the experimental set-ups and postC algorithms utilised, and their associated outcomes in all animal models studied (dog, rabbit, mouse, rat and pig) are discussed. The therapeutic potential of postC is also addressed by discussing reported preliminary studies on the efficacy and feasibility of postC (both ischaemic and pharmacological) in humans.Entities:
Mesh:
Substances:
Year: 2008 PMID: 19104728 PMCID: PMC3971620
Source DB: PubMed Journal: Cardiovasc J Afr ISSN: 1015-9657 Impact factor: 1.167
Several Different Post-C Protocols Applied In Similar In Vivo Rabbit Heart Experiments, As Well As Three Different Protocols In The Mouse Heart, Demonstrating The Experimental Variability Of Post-C
| Iliodromitis | RI | 30 min | 180 min | 4 × 30 sec | IFS | 48.2 ± 4.3 | 45.1 ± 8.9 | NS | Non-protective | |||||||||||
| 6 × 10 sec | 20.4 ± 2.9 | ↓ 57.7 | Protective | |||||||||||||||||
| Chiari | In vivo | RI | 30 min | 180 min | 3 × 10 sec | IFS | 41 ± 2 | 34 ± 3 | NS | Non-protective | ||||||||||
| 3 × 20 sec | 20 ± 3 | ↓ 51 | Protective | |||||||||||||||||
| Argaud | RI | 30 min | 240 min | 4 × 60 sec | IFS | 61 ± 6 | 29 ± 4 | ↓ 52 | Protective | |||||||||||
| 72 h | 48 ± 6 | 20 ± 5 | ↓ 58 | Protective | ||||||||||||||||
| Yang | RI | 40 min | 60 min | 3 × 5 sec | IFS | 51 ± 2 | 37 ± 3 | ↓ 27 | Protective | |||||||||||
| Tsutsumi | RI | 30 min | 120 min | 3 × 20 sec | IFS | 43.4 ± 3.3 | 24.1 ± 3.2 | ↓ 44 | Protective | |||||||||||
| RPP | Pre-ischaemic: 29.9 ± 2.6 | 27.5 ± 2.9 | NS | Maintained heart function | ||||||||||||||||
| Gomez | RI | 60 min | 24 h | 3 × 60 sec | IFS | 56 ± 5 | 39 ± 3 | ↓ 30 | Protective | |||||||||||
RI: regional ischaemia; IFS: infarct size; RPP: rate pressure product (beats.min-1.mmHg.10-3); NS: non-significant.
Postconditioning Of The Rat Heart By Applying 10-Sec Cycle Post-C Protocols
| Penna | GI | 30 min | 120 min | 5 × 10 sec | IFS | 65 ± 4% | 22 ± 4% | ↓ 66 | Protective | |
| LDH release | 1950 ± 100 | 656 ± 93 | ↓ 66 | |||||||
| 15, 20, 25, 30 sec reperfusion with 20, 15, 10, 5 sec ischaemia | IFS | 20 ± 2% | ↓ 69 | Protective | ||||||
| LDH release | 650 ± 60 | ↓ 66 | ||||||||
| Penna | GI | 30 min | 120 min | 5 × 10 sec | IFS | 59 ± 5% | 46 ± 2% | ↓ 22 | Protective | |
| LDH release | 1842 ± 77 | 686 ± 34 | ↓ 63 | |||||||
| 15, 20, 25, 30 sec reperfusion with 20, 15, 10, 5 sec | IFS | 45 ± 2% | ↓ 24 | Protective | ||||||
| LDH release | 675 ± 59 | ↓ 63 | ||||||||
| Tang | Conscious rat | RI | 30 min | 24 h | 6 × 30 sec | IFS | 54.4 ± 2.3% | 55.8 ± 3.5% | NS | Non-protective |
| 6 × 10 sec | 36.1 ± 5.0% | ↓ 34 | Protective | |||||||
| 20 × 10 sec | 28.9 ± 4.9% | ↓ 47 | Protective | |||||||
| 60 × 10 sec | 57.3 ± 5.4% | NS | Non-protective | |||||||
| 45 min | 20 × 10 sec | 62.2 ± 2.4% | 55.4 ± 2.4% | NS | Non-protective | |||||
| 60 min | 20 × 10 sec | 72.7 ± 2.2% | 71.4 ± 3.4% | NS | Non-protective | |||||
RI: regional ischaemia; IFS: infarct size; NS: non-significant; GI: global ischaemia; LDH: lactate dehydrogenase (U/g wet weight).
Unique Post-C Protocols Applied In The Rat Heart To Elicit Protection Against Reperfusion Arrhythmia And Fibrillation, As Well As Post-C Protocols Reported To Be Cardioprotective In The Pig Heart. Each Of These Porcine Studies Utilised Different Post-C Protocols And Experimental Designs
| Galagudza | RI | 30 min | 30 min | 15 min reperfusion + 2 min GI | Ventricular fibrillation | During postC ischaemia: conversion of VF; onset of stable, regular rhythm after postC | Anti-fibrillation effect | |||
| Sasaki | GI | 15 min | 20 min | 1 min reperfusion + 5 min GI | Arrhythmias | Termination of ventricular arrhythmia, thus shorter duration of arrhythmia in postC hearts | Antiarythmic effect | |||
| Jiang | RI | 75 min | 180 min | 3 × 30 sec | IFS | 45 ± 5% | 12 ± 4% | ↓ 73 | Protective | |
| Skyschally | Low flow | 90 min | 120 min | 6 × 20 sec | IFS | 33.8 ± 4.4% | 19.5 ± 2.9% | ↓ 42.3 | Protective | |
| Zhao | RI | 180 min | 120 min | 6 × 10 sec | IFS | 98.5% | 76.1% | ↓ 22.7 | Protective | |
| No-reflow area | 81.3% | 54.3% | ↓ 33.2 | |||||||
| HR | 108 ± 6 | 107 ± 9 | NS | |||||||
| LVSP | 109 ± 3 | 111 ± 2 | ↑ 2 | |||||||
| LVEDP | 6.1 ± 1.6 | 4.9 ± 1.9 | ↓ 19.7 | |||||||
| + dp/dt | 2287 ± 551 | 2759 ± 492 | ↑ 21 | |||||||
| − dp/dt | 2112 ± 242 | 2319 ± 183 | ↑ 10 | |||||||
| CO | 1.34 ± 0.25 | 1.94 ± 0.31 | ↑ 44.78 | |||||||
RI: regional ischaemia; IFS: infarct size; NS: non-significant; GI: global ischaemia; VF: ventricular fibrillation; LVSP: left ventricular systolic pressure (mmHg); LVEDP: left ventricular end-diastolic pressure (mmHg); ± dp/dt: maximal change rate of left ventricular pressure rise and fall (mmHg/sec); CO: cardiac output (l/min).
Summary Of Studies Reported On The Feasibililty Of Post-C In Cellular Preparations
| Sun | Neonatal rat cardiomyocytes | 3 h (hypoxic incubator: 95% N2 5% CO2) | 6 h | 3 × 5 min (switching between normoxic and hypoxic incubators) | PostC reduced cell death (PI staining and LDH release) |
| Reduced ROS generation | |||||
| Reduced intracellular and mitochondrial Ca2+ | |||||
| Sun | Neonatal rat cardiomyocytes | 3 h | 6 h | PostC reduced apoptosis and DNA fragmentation | |
| Associated with: ↓ superoxide generation, ↓ JNK and p38 MAPK activity, ↓ TNF-α release, ↓ caspase 3 and 8 activity, ↓ Bax | |||||
| Zhao | H9c2 cardiac muscle cells | 8 h | 3 h | 3 × 5 min | PostC reduced number of apoptotic cells and DNA fragmentation |
| Associated with: ↓ cytochrome C release, ↓ loss in mitochondral membrane potential and inhibition of mPTP, ↓ Bax and ↑ Bcl-2 in mitochondria, ↑ phospho-PKB/Akt and phospho-ERK in isolated mitochondria | |||||
| Wang | Isolated rat cardiomyocytes | 2 h | 3 h | 2 × 5 min (switching between normoxic and hypoxic incubators) | PostC increased cell viability (assessed with trypan blue staining) and decreased LDH release and apoptosis |
| Associated with reduced ONOO– generation following hypoxia/reoxygenation |
PI: propidium iodide; LDH: lactate dehydrogenade; ROS: reactive oxygen species; JNK: c-Jun NH2-terminal kinase; p38 MAPK: p38 mitogenactivated protein kinase; TNF-α: tumour necrosis factor-α; mPTP: mitochondral permeability transition pore; PKB: protein kinase B; ERK: extracellular signal-regulated kinase; ONOO–: peroxynitrite.
Fig. 1.Overview of the intracellular mechanisms identified to be involved in the cardioprotective mechanism of postC. The intermittent reintroduction of perfusion leads to transient acidosis, which keeps the mPTP closed until the presence of triggering molecules, combined with oxygen, activate pro-survival pathways that maintain the mPTP in a closed conformation after normalisation of the pH. In this model, the mitochondria serve as primary end-effectors of protection. O: opioids; A: adenosine; B: bradykinin; MEK 1/2: MAPK/ERK kinases; ERK 1/2: extracellular signal-regulated kinase; PI3-kinase: phospatidylinositol 3-kinase; PKB: protein kinase B; GSK3β: glycogen synthase kinase 3β; PKC: protein kinase C; NOS: nitric oxide synthase; GC: guanylyl cyclase; mK+ATP- channel: mitochondrial ATP-dependent potassium channel; STAT3: signal transducer and activator of transcription 3; TF: tissue factor.